CTOs on the Move

Allegro Ophthalmics

www.allegroeye.com

 
With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide Therapy TM as the next generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema. The potential to liberate patients from legal blindness to a much improved quality of life sustained by self-sufficient functional vision propels and accelerates our efforts.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.allegroeye.com
  • 31473 Rancho Viejo Road Suite 204
    San Juan Capistrano, CA USA 92675
  • Phone: 949.940.8130

Executives

Name Title Contact Details

Similar Companies

McKesson

McKesson Corporation, currently ranked 7th on the FORTUNE 500, we are a global healthcare services and medical supply company dedicated to delivering better care. We support the entire healthcare system, including pharmacies, hospitals, health systems, biotech and life sciences companies, specialty care and oncology practices, physician offices, surgery centers, and long-term care and home health facilities. We deliver pharmaceutical products, medical supplies and business services to each of these groups to create a world of better health.

DRX

DRX is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Families First Pediatrics

With locations in South Jordan & Riverton Utah, our experienced pediatricians & caring team of professionals provides comprehensive care for your children.

Oyster Point Pharma

Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.

Janssen Pharmaceuticals

Janssen Pharmaceuticals is a Titusville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.